SVB vs. Guggenheim Healthcare? Which Bank is Better in 2022?
which firm is better in healthcare? I know the answer a year or two ago would have hands down been Guggenheim, but SVB has taken major strides in healthcare in the past year, with some of their biggest accomplishments having recently been the lead sell-side advisor in the $6bn sale of LHC Group to UnitedHealth, lead bookrunner on the $3.3bn IPO of Komondo Health this summer, and co-advising on the $1.9bn sale of Zogenix and the $3.3bn sale of Dicerna. Coincidentally, according to Axios, "SVB’s big push into M&A advisory started with the February 2021 appointment of heavy hitter Barry Blake. The bank poached Blake from Guggenheim Securities, naming him global co-head of investment banking. Shortly after, Robert Minear from Guggenheim jumped ship to steer SVB’s financial sponsor origination efforts."
Given all the recent developments, which firm has a better healthcare practice?
Don't have a horse in this race but seems like an odd comparison. SVB poached a few bankers from Gugg and has closed a few big advisory deals but is still a much smaller player. Not a knock on SVB in any way.